Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.

De Fenza M, D'Alonzo D, Esposito A, Munari S, Loberto N, Santangelo A, Lampronti I, Tamanini A, Rossi A, Ranucci S, De Fino I, Bragonzi A, Aureli M, Bassi R, Tironi M, Lippi G, Gambari R, Cabrini G, Palumbo G, Dechecchi MC, Guaragna A.

Eur J Med Chem. 2019 Aug 1;175:63-71. doi: 10.1016/j.ejmech.2019.04.061. Epub 2019 Apr 25.

PMID:
31075609
2.

Aerosolized Bovine Lactoferrin Counteracts Infection, Inflammation and Iron Dysbalance in A Cystic Fibrosis Mouse Model of Pseudomonas aeruginosa Chronic Lung Infection.

Cutone A, Lepanto MS, Rosa L, Scotti MJ, Rossi A, Ranucci S, De Fino I, Bragonzi A, Valenti P, Musci G, Berlutti F.

Int J Mol Sci. 2019 Apr 30;20(9). pii: E2128. doi: 10.3390/ijms20092128.

3.

Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa.

Bianconi I, Alcalá-Franco B, Scarselli M, Dalsass M, Buccato S, Colaprico A, Marchi S, Masignani V, Bragonzi A.

Front Immunol. 2019 Jan 9;9:3021. doi: 10.3389/fimmu.2018.03021. eCollection 2018.

4.

The impact of host genetic background in the Pseudomonas aeruginosa respiratory infections.

Loré NI, Cigana C, Sipione B, Bragonzi A.

Mamm Genome. 2018 Aug;29(7-8):550-557. doi: 10.1007/s00335-018-9753-8. Epub 2018 Jun 12. Review.

PMID:
29947963
5.

Targeting the Bacterial Cytoskeleton of the Burkholderia cepacia Complex for Antimicrobial Development: A Cautionary Tale.

Carnell SC, Perry JD, Borthwick L, Vollmer D, Biboy J, Facchini M, Bragonzi A, Silipo A, Vergunst AC, Vollmer W, Khan ACM, De Soyza A.

Int J Mol Sci. 2018 May 30;19(6). pii: E1604. doi: 10.3390/ijms19061604.

6.

Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection.

Lorè NI, Veraldi N, Riva C, Sipione B, Spagnuolo L, De Fino I, Melessike M, Calzi E, Bragonzi A, Naggi A, Cigana C.

Int J Mol Sci. 2018 Jan 9;19(1). pii: E207. doi: 10.3390/ijms19010207.

7.

Staphylococcus aureus Impacts Pseudomonas aeruginosa Chronic Respiratory Disease in Murine Models.

Cigana C, Bianconi I, Baldan R, De Simone M, Riva C, Sipione B, Rossi G, Cirillo DM, Bragonzi A.

J Infect Dis. 2018 Mar 5;217(6):933-942. doi: 10.1093/infdis/jix621.

PMID:
29216403
8.

Environmental Burkholderia cenocepacia Strain Enhances Fitness by Serial Passages during Long-Term Chronic Airways Infection in Mice.

Bragonzi A, Paroni M, Pirone L, Coladarci I, Ascenzioni F, Bevivino A.

Int J Mol Sci. 2017 Nov 14;18(11). pii: E2417. doi: 10.3390/ijms18112417.

9.

Inflammation and host-pathogen interaction: Cause and consequence in cystic fibrosis lung disease.

Bragonzi A, Horati H, Kerrigan L, Lorè NI, Scholte BJ, Weldon S.

J Cyst Fibros. 2018 Mar;17(2S):S40-S45. doi: 10.1016/j.jcf.2017.10.004. Epub 2017 Oct 27. Review.

PMID:
29107600
10.

Platelet Depletion Impairs Host Defense to Pulmonary Infection with Pseudomonas aeruginosa in Mice.

Amison RT, O'Shaughnessy BG, Arnold S, Cleary SJ, Nandi M, Pitchford SC, Bragonzi A, Page CP.

Am J Respir Cell Mol Biol. 2018 Mar;58(3):331-340. doi: 10.1165/rcmb.2017-0083OC.

PMID:
28957635
11.

The PAPI-1 pathogenicity island-encoded small RNA PesA influences Pseudomonas aeruginosa virulence and modulates pyocin S3 production.

Ferrara S, Falcone M, Macchi R, Bragonzi A, Girelli D, Cariani L, Cigana C, Bertoni G.

PLoS One. 2017 Jun 30;12(6):e0180386. doi: 10.1371/journal.pone.0180386. eCollection 2017.

12.

Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids.

Caretti A, Vasso M, Bonezzi FT, Gallina A, Trinchera M, Rossi A, Adami R, Casas J, Falleni M, Tosi D, Bragonzi A, Ghidoni R, Gelfi C, Signorelli P.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Aug;390(8):775-790. doi: 10.1007/s00210-017-1373-4. Epub 2017 Apr 24.

PMID:
28439630
13.

Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection.

Codagnone M, Cianci E, Lamolinara A, Mari VC, Nespoli A, Isopi E, Mattoscio D, Arita M, Bragonzi A, Iezzi M, Romano M, Recchiuti A.

Mucosal Immunol. 2018 Jan;11(1):35-49. doi: 10.1038/mi.2017.36. Epub 2017 Apr 19.

PMID:
28422188
14.

Aerosolized bovine lactoferrin reduces neutrophils and pro-inflammatory cytokines in mouse models of Pseudomonas aeruginosa lung infections.

Valenti P, Frioni A, Rossi A, Ranucci S, De Fino I, Cutone A, Rosa L, Bragonzi A, Berlutti F.

Biochem Cell Biol. 2017 Feb;95(1):41-47. doi: 10.1139/bcb-2016-0050. Epub 2016 Jul 8.

PMID:
28129511
15.

Dissection of Host Susceptibility to Bacterial Infections and Its Toxins.

Nashef A, Agbaria M, Shusterman A, Lorè NI, Bragonzi A, Wiess E, Houri-Haddad Y, Iraqi FA.

Methods Mol Biol. 2017;1488:551-578.

PMID:
27933544
16.

The shedding-derived soluble receptor for advanced glycation endproducts sustains inflammation during acute Pseudomonas aeruginosa lung infection.

Antonelli A, Di Maggio S, Rejman J, Sanvito F, Rossi A, Catucci A, Gorzanelli A, Bragonzi A, Bianchi ME, Raucci A.

Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):354-364. doi: 10.1016/j.bbagen.2016.11.040. Epub 2016 Nov 30.

PMID:
27913191
17.

The host genetic background defines diverse immune-reactivity and susceptibility to chronic Pseudomonas aeruginosa respiratory infection.

Spagnuolo L, De Simone M, Lorè NI, De Fino I, Basso V, Mondino A, Cigana C, Bragonzi A.

Sci Rep. 2016 Nov 16;6:36924. doi: 10.1038/srep36924.

18.

Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.

Farinelli G, Jofra Hernandez R, Rossi A, Ranucci S, Sanvito F, Migliavacca M, Brombin C, Pramov A, Di Serio C, Bovolenta C, Gentner B, Bragonzi A, Aiuti A.

Mol Ther. 2016 Oct;24(10):1873-1880. doi: 10.1038/mt.2016.150. Epub 2016 Jul 26.

19.

Genotypic and phenotypic relatedness of Pseudomonas aeruginosa isolates among the major cystic fibrosis patient cohort in Italy.

Cigana C, Melotti P, Baldan R, Pedretti E, Pintani E, Iansa P, De Fino I, Favari F, Bergamini G, Tridello G, Cirillo DM, Assael BM, Bragonzi A.

BMC Microbiol. 2016 Jul 11;16(1):142. doi: 10.1186/s12866-016-0760-1.

20.

Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia.

Cigana C, Bernardini F, Facchini M, Alcalá-Franco B, Riva C, De Fino I, Rossi A, Ranucci S, Misson P, Chevalier E, Brodmann M, Schmitt M, Wach A, Dale GE, Obrecht D, Bragonzi A.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4991-5000. doi: 10.1128/AAC.00390-16. Print 2016 Aug.

21.

Role of Iron Uptake Systems in Pseudomonas aeruginosa Virulence and Airway Infection.

Minandri F, Imperi F, Frangipani E, Bonchi C, Visaggio D, Facchini M, Pasquali P, Bragonzi A, Visca P.

Infect Immun. 2016 Jul 21;84(8):2324-2335. doi: 10.1128/IAI.00098-16. Print 2016 Aug.

22.

IL-17A impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa.

Lorè NI, Cigana C, Riva C, De Fino I, Nonis A, Spagnuolo L, Sipione B, Cariani L, Girelli D, Rossi G, Basso V, Colombo C, Mondino A, Bragonzi A.

Sci Rep. 2016 May 18;6:25937. doi: 10.1038/srep25937.

23.

Mapping genetic determinants of host susceptibility to Pseudomonas aeruginosa lung infection in mice.

De Simone M, Spagnuolo L, Lorè NI, Cigana C, De Fino I, Broman KW, Iraqi FA, Bragonzi A.

BMC Genomics. 2016 May 11;17:351. doi: 10.1186/s12864-016-2676-4.

24.

The IL-17A/IL-17RA axis in pulmonary defence and immunopathology.

Lorè NI, Bragonzi A, Cigana C.

Cytokine Growth Factor Rev. 2016 Aug;30:19-27. doi: 10.1016/j.cytogfr.2016.03.009. Epub 2016 Mar 24. Review.

PMID:
27033174
25.

Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections.

Cigana C, Lorè NI, Riva C, De Fino I, Spagnuolo L, Sipione B, Rossi G, Nonis A, Cabrini G, Bragonzi A.

Sci Rep. 2016 Feb 17;6:21465. doi: 10.1038/srep21465.

26.

Comparative genomics and biological characterization of sequential Pseudomonas aeruginosa isolates from persistent airways infection.

Bianconi I, Jeukens J, Freschi L, Alcalá-Franco B, Facchini M, Boyle B, Molinaro A, Kukavica-Ibrulj I, Tümmler B, Levesque RC, Bragonzi A.

BMC Genomics. 2015 Dec 29;16:1105. doi: 10.1186/s12864-015-2276-8.

27.

In vitro and in vivo screening for novel essential cell-envelope proteins in Pseudomonas aeruginosa.

Fernández-Piñar R, Lo Sciuto A, Rossi A, Ranucci S, Bragonzi A, Imperi F.

Sci Rep. 2015 Dec 1;5:17593. doi: 10.1038/srep17593.

28.

Thymidine-Dependent Staphylococcus aureus Small-Colony Variants Are Induced by Trimethoprim-Sulfamethoxazole (SXT) and Have Increased Fitness during SXT Challenge.

Kriegeskorte A, Lorè NI, Bragonzi A, Riva C, Kelkenberg M, Becker K, Proctor RA, Peters G, Kahl BC.

Antimicrob Agents Chemother. 2015 Dec;59(12):7265-72. doi: 10.1128/AAC.00742-15. Epub 2015 Sep 14.

29.

Host genetic diversity influences the severity of Pseudomonas aeruginosa pneumonia in the Collaborative Cross mice.

Lorè NI, Iraqi FA, Bragonzi A.

BMC Genet. 2015 Aug 28;16:106. doi: 10.1186/s12863-015-0260-6.

30.

Activation of Human Toll-like Receptor 4 (TLR4)·Myeloid Differentiation Factor 2 (MD-2) by Hypoacylated Lipopolysaccharide from a Clinical Isolate of Burkholderia cenocepacia.

Di Lorenzo F, Kubik Ł, Oblak A, Lorè NI, Cigana C, Lanzetta R, Parrilli M, Hamad MA, De Soyza A, Silipo A, Jerala R, Bragonzi A, Valvano MA, Martín-Santamaría S, Molinaro A.

J Biol Chem. 2015 Aug 28;290(35):21305-19. doi: 10.1074/jbc.M115.649087. Epub 2015 Jul 9.

31.

Upregulation of TMEM16A Protein in Bronchial Epithelial Cells by Bacterial Pyocyanin.

Caci E, Scudieri P, Di Carlo E, Morelli P, Bruno S, De Fino I, Bragonzi A, Gianotti A, Sondo E, Ferrera L, Palleschi A, Santambrogio L, Ravazzolo R, Galietta LJ.

PLoS One. 2015 Jun 29;10(6):e0131775. doi: 10.1371/journal.pone.0131775. eCollection 2015.

32.

Integrated whole-genome screening for Pseudomonas aeruginosa virulence genes using multiple disease models reveals that pathogenicity is host specific.

Dubern JF, Cigana C, De Simone M, Lazenby J, Juhas M, Schwager S, Bianconi I, Döring G, Eberl L, Williams P, Bragonzi A, Cámara M.

Environ Microbiol. 2015 Nov;17(11):4379-93. doi: 10.1111/1462-2920.12863. Epub 2015 May 14.

33.

Host-pathogen interplay in the respiratory environment of cystic fibrosis.

Yonker LM, Cigana C, Hurley BP, Bragonzi A.

J Cyst Fibros. 2015 Jul;14(4):431-439. doi: 10.1016/j.jcf.2015.02.008. Epub 2015 Mar 19. Review.

34.

Affecting Pseudomonas aeruginosa phenotypic plasticity by quorum sensing dysregulation hampers pathogenicity in murine chronic lung infection.

Bondí R, Messina M, De Fino I, Bragonzi A, Rampioni G, Leoni L.

PLoS One. 2014 Nov 24;9(11):e112105. doi: 10.1371/journal.pone.0112105. eCollection 2014.

35.

Host genetic background influences the response to the opportunistic Pseudomonas aeruginosa infection altering cell-mediated immunity and bacterial replication.

De Simone M, Spagnuolo L, Lorè NI, Rossi G, Cigana C, De Fino I, Iraqi FA, Bragonzi A.

PLoS One. 2014 Sep 30;9(9):e106873. doi: 10.1371/journal.pone.0106873. eCollection 2014.

36.

Inactivation of thyA in Staphylococcus aureus attenuates virulence and has a strong impact on metabolism and virulence gene expression.

Kriegeskorte A, Block D, Drescher M, Windmüller N, Mellmann A, Baum C, Neumann C, Lorè NI, Bragonzi A, Liebau E, Hertel P, Seggewiss J, Becker K, Proctor RA, Peters G, Kahl BC.

MBio. 2014 Jul 29;5(4):e01447-14. doi: 10.1128/mBio.01447-14.

37.

Persistent cystic fibrosis isolate Pseudomonas aeruginosa strain RP73 exhibits an under-acylated LPS structure responsible of its low inflammatory activity.

Di Lorenzo F, Silipo A, Bianconi I, Lore' NI, Scamporrino A, Sturiale L, Garozzo D, Lanzetta R, Parrilli M, Bragonzi A, Molinaro A.

Mol Immunol. 2015 Feb;63(2):166-75. doi: 10.1016/j.molimm.2014.04.004. Epub 2014 May 22.

PMID:
24856407
38.

Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection.

Kukavica-Ibrulj I, Facchini M, Cigana C, Levesque RC, Bragonzi A.

Methods Mol Biol. 2014;1149:757-71. doi: 10.1007/978-1-4939-0473-0_58.

PMID:
24818948
39.

Long term chronic Pseudomonas aeruginosa airway infection in mice.

Facchini M, De Fino I, Riva C, Bragonzi A.

J Vis Exp. 2014 Mar 17;(85). doi: 10.3791/51019.

40.

Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infection.

Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, Di Serio C, Bragonzi A, Cirillo DM.

PLoS One. 2014 Mar 6;9(3):e89614. doi: 10.1371/journal.pone.0089614. eCollection 2014.

41.

Pseudomonas aeruginosa reduces the expression of CFTR via post-translational modification of NHERF1.

Rubino R, Bezzerri V, Favia M, Facchini M, Tebon M, Singh AK, Riederer B, Seidler U, Iannucci A, Bragonzi A, Cabrini G, Reshkin SJ, Tamanini A.

Pflugers Arch. 2014 Dec;466(12):2269-78. doi: 10.1007/s00424-014-1474-6. Epub 2014 Mar 5.

PMID:
24595473
42.

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.

Döring G, Bragonzi A, Paroni M, Aktürk FF, Cigana C, Schmidt A, Gilpin D, Heyder S, Born T, Smaczny C, Kohlhäufl M, Wagner TO, Loebinger MR, Bilton D, Tunney MM, Elborn JS, Pier GB, Konstan MW, Ulrich M.

J Cyst Fibros. 2014 Mar;13(2):156-63. doi: 10.1016/j.jcf.2013.10.007. Epub 2013 Oct 31.

43.

Extended Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation.

Hirschhausen N, Block D, Bianconi I, Bragonzi A, Birtel J, Lee JC, Dübbers A, Küster P, Kahl J, Peters G, Kahl BC.

Int J Med Microbiol. 2013 Dec;303(8):685-92. doi: 10.1016/j.ijmm.2013.09.012. Epub 2013 Oct 8.

PMID:
24183484
44.

Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis.

Caretti A, Bragonzi A, Facchini M, De Fino I, Riva C, Gasco P, Musicanti C, Casas J, Fabriàs G, Ghidoni R, Signorelli P.

Biochim Biophys Acta. 2014 Jan;1840(1):586-94. doi: 10.1016/j.bbagen.2013.10.018. Epub 2013 Oct 18.

45.

Complete Genome Sequence of Persistent Cystic Fibrosis Isolate Pseudomonas aeruginosa Strain RP73.

Jeukens J, Boyle B, Bianconi I, Kukavica-Ibrulj I, Tümmler B, Bragonzi A, Levesque RC.

Genome Announc. 2013 Aug 1;1(4). pii: e00568-13. doi: 10.1128/genomeA.00568-13.

46.

Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity.

Imperi F, Massai F, Facchini M, Frangipani E, Visaggio D, Leoni L, Bragonzi A, Visca P.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7458-63. doi: 10.1073/pnas.1222706110. Epub 2013 Apr 8. Erratum in: Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16693.

47.

Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response.

Bragonzi A, Farulla I, Paroni M, Twomey KB, Pirone L, Lorè NI, Bianconi I, Dalmastri C, Ryan RP, Bevivino A.

PLoS One. 2012;7(12):e52330. doi: 10.1371/journal.pone.0052330. Epub 2012 Dec 21.

48.

Analysis of Pseudomonas aeruginosa cell envelope proteome by capture of surface-exposed proteins on activated magnetic nanoparticles.

Vecchietti D, Di Silvestre D, Miriani M, Bonomi F, Marengo M, Bragonzi A, Cova L, Franceschi E, Mauri P, Bertoni G.

PLoS One. 2012;7(11):e51062. doi: 10.1371/journal.pone.0051062. Epub 2012 Nov 30.

49.

Response of CFTR-deficient mice to long-term chronic Pseudomonas aeruginosa infection and PTX3 therapy.

Paroni M, Moalli F, Nebuloni M, Pasqualini F, Bonfield T, Nonis A, Mantovani A, Garlanda C, Bragonzi A.

J Infect Dis. 2013 Jul;208(1):130-8. doi: 10.1093/infdis/jis636. Epub 2012 Oct 18.

50.

Factors contributing to epidemic MRSA clones replacement in a hospital setting.

Baldan R, Testa F, Lorè NI, Bragonzi A, Cichero P, Ossi C, Biancardi A, Nizzero P, Moro M, Cirillo DM.

PLoS One. 2012;7(8):e43153. doi: 10.1371/journal.pone.0043153. Epub 2012 Aug 14.

Supplemental Content

Loading ...
Support Center